Latest Capital Raising And Placements News

Biotron Limited has advanced its Hepatitis B antiviral program while preparing to acquire Sedarex Limited, backed by a $2.5 million capital raise. The move signals a strategic expansion into safer anaesthetics alongside ongoing R&D progress.

Pivotal Metals Limited has announced a C$2.6 million flow-through share offer targeting Canadian investors, aimed at funding critical minerals exploration in Quebec. The offer complements a concurrent institutional placement, underscoring the company’s aggressive growth strategy amid significant operational risks.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Lachlan Star Limited reports robust gold mineralisation at its Killaloe Project in Western Australia and progresses maiden drilling at North Cobar in New South Wales, supported by a $2.16 million capital raise.

Australian Oil Company Limited has announced an $800,000 capital raising through a two-tranche share placement aimed at advancing its Californian oil and gas projects and exploring new growth opportunities.

LGI Limited has secured $56.2 million through a fully underwritten institutional placement and a Share Purchase Plan to fast-track its renewable energy projects and expand operating capacity beyond 80 MW. The capital raise underpins the company’s strategic growth in landfill biogas recovery and battery storage solutions amid rising energy market volatility.

Manuka Resources has raised A$15 million to accelerate production at its Wonawinta Silver Mine and fund exploration drilling at Mt Boppy and Pipeline Ridge in New South Wales.

European Lithium has offloaded an additional US$50 million worth of Critical Metals Corp shares, coinciding with CRML’s own US$50 million capital raise to advance its Greenland rare earth project.

Brazilian Rare Earths Limited has raised A$120 million through a share placement to fast-track its high-grade rare earth projects and integrated refinery development in Brazil.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.